Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4439280 | 0.82 | SLC6A4 (0.53) | NPBWR1MCHR1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4438697 | 0.80 | AR (0.50) | EPAS1SLC6A2SLC6A3SLC6A4AR | |
| SCHEMBL13970688 | 0.80 | EPAS1 (0.49) | EPAS1SLC6A2SLC6A3SLC6A4MRGPRX4 | |
| SCHEMBL4434971 | 0.79 | SLC6A4 (0.54) | SLC6A2SLC6A3SLC6A4SCN8ASCN10A | |
| SCHEMBL4440723 | 0.78 | MEN1 (0.48) | SLC6A2SLC6A3SLC6A4ARMRGPRX4 | |
| SCHEMBL7467276 | 0.77 | NR4A2 (0.43) | NPBWR1MCHR1SLC6A4PIK3CDPIK3CA | |
| SCHEMBL4445105 | 0.75 | SCN8A (0.49) | EPAS1NPBWR1MCHR1SLC6A2SLC6A3 | |
| SCHEMBL4437986 | 0.74 | SLC6A4 (0.48) | NPBWR1MCHR1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4704057 | 0.72 | SLC6A4 (0.43) | EPAS1SLC6A2SLC6A3SLC6A4MRGPRX4 | |
| SCHEMBL1340366 | 0.72 | L3MBTL1 (0.59) | EPAS1SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101622227-A | Biaryl and biheteroaryl compounds useful in treating iron disorders | XENON PHARMACEUTICALS INC | 2010-01-06 | — | — | CN | disclosed |
| EP-2061754-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008115999-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | FECH, SLC10A1, SLC40A1 | EPAS1 2035/4885NPBWR1 1543/4885MCHR1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.